



---

**Utilization \*ALERT\***

- Prior to use of this MCP for evaluation of medical necessity, benefit coverage MUST be verified in the member's EOC or benefit document.
  - This policy applies only to members whose benefit plans cover infertility services. The member benefits (EOC or brochure or Medicaid handbook) are the primary source of benefit coverage, and all coverage is subject to the terms and conditions of the member's benefit plan;
  - Coverage varies widely for diagnosis and treatment of infertility, and in exclusions and limitations of procedures.
  - Many members have a high-cost share (up to 50%) for services related to evaluating and treating infertility physicians and medical center staff should provide resources for cost estimates to assist members in their treatment decisions.
- 

I. Procedure: **Infertility diagnosis and treatment**  
Related Medical Coverage Policies: Preimplantation Genetic Testing (PGT), Fertility preservation for Iatrogenic Infertility

II. Diagnoses: **Female and Male Infertility**

III. Specialties/Services: OB/GYN, Urology, Reproductive Endocrinology, Laboratory and Radiology

**IV. Definition of Infertility**

Kaiser Permanente Mid-Atlantic States (KPMAS) defines infertility as one of the following:

- A. He or she (female is younger than 35) is unable to conceive or produce conception after one year of frequent, unprotected heterosexual sexual intercourse OR
- B. For a female 35 years of age or older, she is unable to conceive or produce conception after six months of frequent, unprotected heterosexual sexual intercourse OR
- C. Women with known tubal or other infertility disease (e.g., Polycystic ovary syndrome) OR
- D. Women planning to use donor sperm for artificial insemination OR
- E. Same sex couples, where mandated per jurisdiction or line of business, OR
- F. Opposite sex couples with known male-factor infertility OR
- G. Female patients who have undergone early menopause. Per ASRM Premature Ovarian Failure is the cessation of menstrual periods due to failure of the ovaries before age 40 OR
- H. Maryland Situs members with a diagnosis of recurrent pregnancy loss defined as the documentation of two or more consecutive failed pregnancies confirmed by pregnancy test or ultrasound OR
- I. Single women or couples who have a genetic condition that meets the KP-MAS Preimplantation Genetic Testing MCP criteria for PGT-M or PGT-SR
- J. Women who are post-menopausal (Postmenopausal: After menopause, the period of time after a woman



has experienced 12 consecutive months without menstruation) are NOT considered infertile unless they are less than age 40 as per ASRM

- K. Single women requesting oocyte retrieval and freezing for future pregnancy attempts are NOT considered to be infertile unless they meet the medical necessity criteria per the KP-MAS Fertility Preservation Medical Coverage Policy

## **V. Patient Workup**

Prior to referral to infertility provider or a Reproductive Endocrinologist Infertility specialist (REI), the primary care Obstetrician/Gynecologist must perform or confirm the following diagnostic studies for both the male and female, as applicable. Female members must have the testing/documentation performed by their primary care gynecologist. Except for the Pap smear (A1), all services are subject to infertility cost share as determined by member's benefit contract.

### **A. Female Factor Workup - Initial referrals**

1. Pap smear up to date as per ACOG (American College of Obstetricians and Gynecologists) guidelines and GC/Chlamydia cultures (mycoplasma if necessary) as indicated.
2. HIV, Syphilis IgG, HBsAg, Hep C core Ab
3. Complete Blood Count (CBC), hemoglobin electrophoresis as indicated
4. ABO blood type (unless documented)
5. Rubella, VZV (Varicella Zoster Virus) IgG (if not documented immune)
6. Hormonal Studies within 13 months
  - a. AM Day 3 Follicle Stimulating Hormone (FSH);
  - b. Luteinizing Hormone (LH);
  - c. Estradiol (aka E2-Estrogen);
  - d. Thyroid Stimulating Hormone (TSH);
  - e. Fasting AM Prolactin (if a patient does not have normal menstrual cycles); *and*
  - f. Anti-Mullerian Hormone (AMH)
7. Hysterosalpingogram (HSG) or diagnostic laparoscopy within the past 2 years unless there is a previous HSG which shows bilateral tubal occlusion at any time in the past, and there has been no tubal surgery subsequent to the HSG. This requirement is waived if this member meets the criteria for infertility consultation due to a genetic condition supported by our Preimplantation Genetic Testing MCP as IVF will be required.

### **B. Male Factor Workup – Initial referrals**

1. Semen analysis (SA) within 1 year.
2. HBs Ag, HCV core Ab, Syphilis IgG, and HIV within one year. Neisseria gonorrhoea and chlamydia testing, if indicated.
3. Referral to Urology (within the member's service delivery option, (MAPMG for HMO Sig) as indicated for abnormal parameters.
4. If a previous semen analysis and urology workup indicates any of the following, an additional SA and/or a repeat urology work up is not required:

- a. Absence of sperm; or
- b. An uncorrectable and permanent condition; or
- c. A thorough urology work up with no subsequent surgical recommendations

**VI. Initial Specialist Consultation Referral - Female**

After completing the above evaluations, the Obstetrician/Gynecologist may determine that the member requires further evaluation and/or treatment by a participating Reproductive Endocrinology and Infertility (REI) specialist.

- A. The initial referral to an REI specialist should be limited to two consultation visits. The purpose of these visits is to obtain recommendations from the infertility specialist regarding the member's options for infertility
- B. The initial referral for two visits should be accompanied by appropriate medical records, radiology, and lab results. These may be forwarded to the specialist through release of medical records, accessed by the REI specialist through Affiliate Link or be hand-carried by the member. (All labs and tests should be completed before referral);
- C. REI consult includes endo-vaginal ultrasound with antral follicle count to assess ovarian functional status, as appropriate.
- D. Referrals for additional consultation visits will be reviewed on a case-by-case basis and will not be covered if there is documentation that the required testing was completed prior to the initial consultation and no further evaluation or procedures are needed to make treatment recommendations.

**VII. Female Fertility Treatment Referrals**

- A. Upon receipt of a satisfactory fertility treatment plan from the REI specialist, the REI specialist should enter a referral with a request for the specific treatment and the appropriate number of visits required.
- B. All referral requests include individual consideration of the patient's age, history, comorbid conditions, and outcome prognosis for each treatment, including the level of care required.
- C. Any questions regarding appropriateness of treatment plans must be reviewed by the Utilization Management Operations Center (UMOC) UM Referral Management physician, and/or the Regional Ob/Gyn Consultant for Infertility Referral Management.
- D. Stages of treatment are sequential and progressive; all referrals for infertility treatment expire in 180 days.

**VIII. Female Treatments**

**A. Basic Infertility Treatment**

Up to 6 cycles of Basic Infertility Treatment (IUI (Intrauterine insemination)) are generally authorized for Natural cycle/IUI and any combination of six cycles of drug+ IUI per live birth:



1. Natural cycle/ovulation kit/intrauterine insemination (IUI) -- 12 visits per referral up to 4-6 cycles
2. Clomid, Femara (Letrozole) or other drug up to 3 cycles, 12 visits per referral
3. Clomid/FSH/IUI (injectable gonadotropins) -- up to 3 cycles, 18 visits per referral. Once gonadotropins are in use, management will be with the Reproductive Endocrinologist.
4. FSH/IUI – up to 3 cycles, 24 visits per referral.
5. For cycles using FSH, all lab work required during the cycle and ultrasound follicular monitoring will be done through the Reproductive Endocrinology and Infertility (REI) office.
6. For HMO members, the referring provider should order preliminary labs to be done at KPMAS medical centers.

**B. Advanced Reproductive (infertility) Treatments**

1. IVF – up to 15 visits per referral. One cycle of IVF will be authorized at a time. A cycle of IVF is counted once oocyte retrieval is completed. A completed IVF cycle includes IVF with fresh embryo transfer or IVF with frozen embryo transfer. Another egg retrieval to create more embryos will not be authorized if a patient is less than 35 years old and has 3 cryopreserved embryos or 35 years and older and has 4 embryos of similar development stage and reasonable quality for transfer.
2. Frozen embryo transfer (FET) – each FET counting as an IVF attempt, 7 visits per referral.
3. For cycles using FSH, the Reproductive Endocrinologist's office orders all lab work required during the cycle and ultrasound follicular monitoring. (For HMO Signature members, preliminary labs should be done by the referring provider at the medical centers).
4. ICSI, when IVF is covered for either the male or the female partner for the following indications:
  - a. Where there is azoospermia (obstructive or non-obstructive) or severe deficits in semen quality or quantity (asthenospermia, teratospermia or oligospermia) demonstrated on two separate occasions at least 2 weeks apart. See Section XI for definitions.
  - b. When the male patient has had cancer and has cryopreserved sperm /frozen sperm collected prior to cancer treatment, which may be limited in number and quality.
  - c. When there has been a previous IVF cycle with less than 50% fertilization of the eggs.
  - d. When a patient is approved for preimplantation genetic diagnosis (PGT-M or PGT-SR) as per the Preimplantation Genetic Diagnosis (Preimplantation Genetic Testing) medical coverage policy.
  - e. ICSI is NOT covered when using donor sperm
5. Assisted Hatching when the member has the IVF benefit.
  - a. Assisted embryo hatching is covered for all Frozen Embryo Transfer (FET) cycles.
  - b. Assisted hatching is covered for IVF cycles for women with ANY of the following:
    - i. 38 years of age or older at time of embryo transfer (ET);
    - ii. An elevated day-3 FSH;
    - iii. Who have previously failed 2 cycles or more of IVF
  - c. Assisted hatching is also covered as an adjunct procedure to Preimplantation Genetic Testing (PGT-M, PGT-SR) when IVF is covered.



6. Endometrial receptivity testing (e.g., endometrial receptivity array (ERA), integrin testing, beta-3 integrin test) are considered investigational and experimental and are not covered for any indication.

**C. General Instructions**

1. Instruct members under treatment by a REI specialist to call the treating physician's answering service for questions related to the care she is receiving, or medical problems related to infertility.
2. If she is unable to reach the specialist or his or her covering physician, instruct the member to call the Kaiser Permanente Member Services call center, which will forward the call to the covering MAPMG Ob/Gyn in her service area.
3. After providing documentation of a positive pregnancy test, the REI specialist cares for the patient and then releases the member to the home center MAPMG Ob/Gyn Department for prenatal care, usually at 6 – 8 weeks. Once the care is transferred to the MAPMG Ob/Gyn provider, the care is expected to remain there.

**IX. Male factor workup, Infertility Specialist Referrals and Treatments**

**A. Male Factor Workup**

1. Semen analysis;
2. Infectious Disease Blood Work: Hep C core antibody, HBsAg, syphilis IgG, HIV, Neisseria gonorrhoea and chlamydia (if indicated)

**B. Infertility Specialist Referrals**

1. Initial urology consults must occur within the Members service delivery option (MAPMG for HMO Sig) before referrals can be authorized to a urologist specializing in male infertility.
2. Additionally, referral to male infertility specialists is indicated if:
  - a. IVF and Intra-cytoplasmic sperm injection (ICSI) is a covered benefit of the male partner (not excluded per EOC) AND
  - b. The male will require a sperm extraction procedure OR
  - c. ICSI will be required, and the female partner does not have the ICSI benefit

**X. Male infertility Treatments**

- A. Sperm extraction for male factor infertility meets criteria for coverage only when the male partner has IVF as a covered benefit and a confirmed diagnosis of azoospermia (a complete absence of sperm in the ejaculate) or documented irreversible inability to ejaculate.
- B. The following sperm functions tests are considered **experimental and investigational** so are not covered benefits.
  1. Acrosome reaction test;
  2. Comet assay;
  3. Computer-assisted sperm analysis (CASA)/computer-assisted sperm motion analysis;
  4. Hemizona assay;
  5. Hyaluronan binding assay;



6. Hypoosmotic swelling test;
7. In vitro testing of sperm penetration;
8. Reactive oxygen species (ROS) test;
9. Sperm chromatin assay;
10. Sperm DNA condensation test;
11. Sperm DNA fragmentation assay;
12. Sperm nucleus maturation; and
13. TUNEL assay

## **XI. Definitions**

- A.** Normal semen parameters
  1. Semen volume: 1.4 ml or more
  2. Sperm concentration: 15 million spermatozoa per ml or more
  3. Total sperm number: 39 million spermatozoa per ejaculate or more
  4. Total motility (percentage of progressive motility and non-progressive motility): 42% or more motile or 30% or more with progressive motility
  5. Vitality: 54% or more live spermatozoa
- B.** Azoospermia: a complete absence of sperm in the ejaculate. Can be obstructive or non-obstructive
- C.** Oligospermia: less than 15 million spermatozoa per ml
- D.** Asthenospermia: less than 42 % motile sperm or less than 30% with progressive motility
- E.** Teratospermia: less than 4% normal sperm morphology

## **References**

1. American Society for Reproductive Medicine, "Role of assisted hatching in in vitro fertilization: a guideline. *Fertility and Sterility*, Aug 2014. 102(2). 196-98.
2. Esteves SC. What every gynecologist should know about male infertility: an update. - *Arch Gynecol Obstet* – Jul 2012; 286(1): 217-29.
3. Gadducci A, Cosio S, Genazzani AR. Ovarian function and childbearing issues in breast cancer survivors. *Gynecological Endocrinology* 2007;23(11):625-31.
4. Harris ID, Missmer SA, Hornstein MD. Poor success of gonadotropin-induced controlled ovarian hyperstimulation and intrauterine insemination for older women. *Fertility and Sterility* 2010;94(1):144-8.
5. Loren AW, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *Journal of Clinical Oncology* 2013;31(19):2500-10.
6. Luk J. Endocrine disorders and medically assisted procreation. *Minerva Ginecologica* 2011;63(2):157-69.
7. McGovern PG, et al. Utility of screening for other causes of infertility in women with "known" polycystic ovary syndrome. *Fertility and Sterility* 2007;87(2):442-4.
8. Medicare CMS, no records returned for this section. Searched 08/03/2017.
9. Myers ER, et al. Effectiveness of assisted reproductive technology (ART). *Evidence Report/Technology Assessment* 2008;(167):1-195.
10. Opoien HK, Fedorcsak P, Byholm T, Tanbo T. Complete surgical removal of minimal and mild endometriosis improves outcome of subsequent IVF/ICSI treatment. *Reproductive Biomedicine Online* 2011; 23(3):389-95.



11. Proctor M, Johnson N, van Peperstraten AM, Phillipson G. Techniques for surgical retrieval of sperm prior to intra-cytoplasmic sperm injection (ICSI) for azoospermia. *Cochrane Database of Systematic Reviews* 2008, Issue 2. Art. No.: CD002807.
12. Stahl PJ. A decade of experience emphasizes that testing for Y microdeletions is essential in American men with azoospermia and severe oligozoospermia. - *Fertil Steril* Oct 2010; 94(5): 1753-6.
13. Turunc T. ICSI Conventional testicular sperm extraction combined with the microdissection technique in nonobstructive azoospermic patients: a prospective comparative study. *Fertil Steril* – Nov 2010; 94(6): 2157-60.
14. Unuane D, Tournaye H, Velkeniers B, Poppe K. Endocrine disorders & female infertility. *Best Practice and Research. Clinical Endocrinology and Metabolism* 2011;25(6):861-73.
15. Walls M. IVF versus ICSI for the fertilization of in-vitro matured human oocytes. - *Reprod Biomed Online* – Dec 2012; 25(6): 603-7.
16. Watrelot A, Chauvin G. Current practice in tubal surgery and adhesion management: a review. *Reproductive Biomedicine Online* 2011;23(1):53-62.
17. Assisted hatching of human embryos: a systematic review and meta-analysis of randomized controlled trials. *Martins WP, Rocha IA, Ferriani RA, Nastro CO*, - *Hum. Reprod. Update* - July 1, 2011; 17 (4); 438-53.
18. Risk of major congenital anomalies after assisted hatching: analysis of three-year data from the national assisted reproduction. *Fertility and Sterility*, Jwa, Junna, MD; Jwa, Seung Chik, MD, Ph.D, M.P.H. Published July 1, 2015. Volume 104, Issue 1. Pages 71-78 © 2015.
19. Liu, Kimberly E.; Case, Allison. SOGC Clinical Practice Guideline: No 346-Advanced Reproductive Age and Fertility. *Journal of Obstetrics and Gynecology. Canada*. August 2017 39(8) 685-695 Language: English DOI: 10.1016/j.jogc.2016.12.004, Database: ScienceDirect.
20. Sauer, Mark, V. Views and reviews: Reproduction at an advanced maternal age and maternal health. *Fertility and Sterility*. May 2015 103(5): 1136-1143 Language: English DOI: 10.1016/j.fertnstert.2015.03.004, Database: Science Direct.
21. Center for Medicare and Medicaid Services (CMS). Medicare Benefit Policy Manual – Chapter 15. Covered Medical and Other Health Services (Rev 256, 02-01-19). Sec 20. Physician expenses for Surgery, childbirth and Treatment for Infertility (Rev.1, 20-01-03). <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c15.pdf>
22. Center for Medicare and Medicaid Services (CMS). Medicare Benefit Policy Manual – Chapter 1. Inpatient Hospital Services Covered Under part A. (Rev 234, 03-10-17). Sec 100 Treatment for Infertility. (Rev.1, 10-01-03) <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c01.pdf>
23. Bassil, Rawad; Casper, Robert; Samara, Nivin; Hsieh, Tzu-Bou; Barzilay, Eran; Orvieto, Raoul; Haas, Jigal. Does the endometrial receptivity array really provide personalized embryo transfer? *Journal of Assisted Reproduction & Genetics*. Jul2018, Vol. 35 Issue 7, p1301-1305. 5p. DOI: 10.1007/s10815-018-1190-9.
24. Liu, Hui; Zhao, Haibin; Yu, Guanling; Li, Mei; Ma, Shuiying; Zhang, Haozhen; Wu, Keliang; Conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI): which is preferred for advanced age patients with five or fewer oocytes retrieved? *Archives of Gynecology & Obstetrics*, May2018; 297(5): 1301-1306. 6p
25. Fertility Problems: Assessment and Treatment. NICE Clinical Guidance CG156 [Internet] National Institute for Health and Care Excellence. 2017 Sept. Accessed 4/16/2020 <https://www.nice.org.uk/guidance/>.
26. Cryopreservation to preserve fertility in people diagnosed with cancer. NICE Pathway last updated: 03 September 2019. <https://pathways.nice.org.uk/pathways/fertily>.



27. Fertility overview. NICE Pathways. last updated: 03 September 2019  
<https://pathways.nice.org.uk/pathways/fertility>
28. [Fainberg J](#), [Kashanian JA](#) Recent advances in understanding and managing male infertility. [F1000Res](#). 2019 May 16;8. pii: F1000 Faculty Rev-670. doi: 10.12688/f1000research.17076.1.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524745/pdf/f1000research-8-18670.pdf>
29. [Babakhanzadeh,E](#), [Nazari,M](#), [Ghasemifar, S](#) and [Khodadadian, A](#). Some of the Factors Involved in Male Infertility: A Prospective Review. *Int J Gen Med*. 2020; 13: 29–41. 2020 Feb 5. doi: [10.2147/IJGM.S241099](#)  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008178/>
30. ACOG Committee Opinion No. 781. American College of Obstetricians and Gynecologists Infertility workup for the women's health specialist. *Obstet Gynecol* 2019;133: e377–84.  
<https://www.acog.org/-/media/project/acog/acogorg/clinical/files/committee-opinion/articles/2019/06/infertility-workup-for-the-womens-health-specialist.pdf>
31. [Freytag D](#), [Gunther V](#), [Maass N](#), [Alkatout I](#). Uterine fibroids and infertility. *Diagnostics* 2021;11(8):2759. DOI: 10.3390/diagnostics11081455. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391505/pdf/diagnostics-11-01455.pdf>
32. Practice Committee of the American Society for Reproductive Medicine. Electronic address: [asm@asm.org](mailto:asm@asm.org), Practice Committee of the American Society for Reproductive Medicine. Evidence-based treatments for couples with unexplained infertility: a guideline. *Fertility and Sterility* 2020;113(2):305-322. DOI: 10.1016/j.fertnstert.2019.10.014. <https://pubmed.ncbi.nlm.nih.gov/32106976/>
33. [Buckett W](#), [Sierra S](#). The management of unexplained infertility: an evidence-based guideline from the Canadian Fertility and Andrology Society. *Reproductive Biomedicine Online* 2019;39(4):633-640. DOI: 10.1016/j.rbmo.2019.05.023. <https://pubmed.ncbi.nlm.nih.gov/32106976/>
34. MCG 28<sup>th</sup> edition. Copyright 2024 MCG Health, LLC. RMG: R-0193 (AC) Infertility – Referral Management; Accessed 12/21/2024
35. Guideline Group on Unexplained Infertility, [Romualdi, D.](#), [Ata, B.](#), [Bhattacharya, S.](#), [Bosch, E.](#), [Costello, M.](#), [Gersak, K.](#), [Homburg, R.](#), [Mincheva, M.](#), [Norman, R. J.](#), [Piltonen, T.](#), [Dos Santos-Ribeiro, S.](#), [Scicluna, D.](#), [Somers, S.](#), [Sunkara, S. K.](#), [Verhoeve, H. R.](#), & [Le Clef, N.](#) (2023). Evidence-based guideline: unexplained infertility†. *Human reproduction (Oxford, England)*, 38(10), 1881–1890. <https://doi.org/10.1093/humrep/dead150>
36. [Massin, N.](#), [Abdennebi, I.](#), [Porcu-Buisson, G.](#), [Chevalier, N.](#), [Descat, E.](#), [Piétin-Vialle, C.](#), [Goro, S.](#), [Brussieux, M.](#), [Pinto, M.](#), [Pasquier, M.](#), & [Bry-Gaillard, H.](#) (2023). The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF. *Human reproduction (Oxford, England)*, 38(5), 927–937.  
<https://doi.org/10.1093/humrep/dead038>
37. [Wang, Y.](#), [Li, R.](#), [Yang, R.](#), [Zheng, D.](#), [Zeng, L.](#), [Lian, Y.](#), [Zhu, Y.](#), [Zhao, J.](#), [Liang, X.](#), [Li, W.](#), [Liu, J.](#), [Tang, L.](#), [Cao, Y.](#), [Hao, G.](#), [Wang, H.](#), [Zhang, H.](#), [Wang, R.](#), [Mol, B. W.](#), [Huang, H.](#), & [Qiao, J.](#) (2024). Intracytoplasmic sperm injection versus conventional in-vitro fertilisation for couples with infertility with non-severe male factor: a multicentre, open-label, randomised controlled trial. *Lancet (London, England)*, 403(10430), 924–934.  
[https://doi.org/10.1016/S0140-6736\(23\)02416-9](https://doi.org/10.1016/S0140-6736(23)02416-9)





**KAISER PERMANENTE**  
Mid-Atlantic States

## Infertility - Diagnosis and Treatment

### Medical Coverage Policy

#### Approval History

Date approved by RUMC*	Date filed with the State of Maryland	Date of Implementation (Ten days after filing)
09/13/2011	09/15/2011	09/26/2011
02/28/2012	02/29/2012	03/11/2012
03/20/2012	Refiled1 03/21/2012	04/01/2012
10/30/2012	11/01/2012	11/12/2012
02/27/2013	02/27/2013	03/10/2013
07/31/2013	08/01/2013	08/11/2013
02/26/2014	02/27/2014	03/09/2014
02/25/2015	02/27/2015	03/10/2015
02/25/2016	02/29/2016	03/11/2016
05/27/2016	05/31/2016	06/10/2016

#### Approval History

Effective June 01, 2016, state filing is no longer required per Maryland House Bill [HB 798](#) – Health Insurance – Reporting

Date approved by RUMC	Date of Implementation
08/29/2016	08/29/2016
08/29/2017	08/29/2017
08/29/2018	08/29/2018
08/28/2019	08/28/2019
08/26/2020	08/26/2020
08/17/2021	08/30/2021
09/27/2021	09/27/2021
01/24/2022	01/24/2022
05/25/2022	05/25/2022
04/25/2023	04/25/2023
12/21/2023	12/21/2023
12/23/2024	12/23/2024

\*The Regional Utilization Management Committee received delegated authority in 2011 to review and approve designated Utilization Management and Medical Coverage Policies by the Regional Quality Improvement Committee.

Note: Kaiser Permanente Mid-Atlantic States (KPMAS) include referral and authorization criteria to support primary care and specialty care practitioners, as appropriate, in caring for members with selected conditions. Medical Coverage Policies are not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by a practitioner in any particular set of circumstances for an individual member.

©2024, Kaiser Foundation Health Plan of the Mid-Atlantic States, Inc.  
©2024, Mid-Atlantic Permanente Medical Group, P.C.